AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15576069 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone test
Number of subjects: 28
Study 15576069 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined metyrapone/low‐dose dexamethasone test
Number of subjects: 28
Study 15576069 — intervention group
Group type: COMPARATOR
Intervention: Visual analogue scale ratings of anxiety, tension, restlessness, and Beck Depression Inventory scores
Number of subjects: 28
Study 11797027 — intervention group
Group type: COMPARATOR
Intervention: Dopexamine (0.5 microg kg(‐1) min(‐1))
Number of subjects: 32
Study 11797027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (1 microg kg(‐1) min(‐1))
Number of subjects: 32
Study 11797027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (5 microg kg(‐1) min(‐1))
Number of subjects: 32
Study 11797027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 11797027 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine and dopamine
Number of subjects: 32
Study 11361908 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychologic testing in asymptomatic HIV-positive children
Number of subjects: 8
Study 11361908 — intervention group
Group type: COMPARATOR
Intervention: Seroreverted children
Number of subjects: 8
Study 8066866 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA capsules (3.6 g)
Number of subjects: 51
Study 8066866 — intervention group
Group type: COMPARATOR
Intervention: Control group (six capsules with a fat composition averaging the Danish diet)
Number of subjects: 51
Study 3167242 — intervention group
Group type: EXPERIMENTAL
Intervention: Male Type A child vignette
Number of subjects: 210
Study 3167242 — intervention group
Group type: EXPERIMENTAL
Intervention: Female Type A child vignette
Number of subjects: 210
Study 3167242 — intervention group
Group type: COMPARATOR
Intervention: Male Type B child vignette
Number of subjects: 210
Study 3167242 — intervention group
Group type: COMPARATOR
Intervention: Female Type B child vignette
Number of subjects: 210
Study 662550 — intervention group
Group type: EXPERIMENTAL
Intervention: Field-independent group
Number of subjects: 50
Study 662550 — intervention group
Group type: COMPARATOR
Intervention: Field-dependent group
Number of subjects: 50
Study 31773211 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-063
Number of subjects: 27
Study 31773211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30859038 — intervention group
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 24 U
Number of subjects: 417
Study 30859038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study 28982497 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel treatment for one year
Number of subjects: 3602
Study 25515914 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulatory intervention
Number of subjects: 253
Study 25515914 — intervention group
Group type: COMPARATOR
Intervention: Standard educational condition
Number of subjects: 253
Study 23931153 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial screening for perinatal depression, IPV, and substance use problems
Number of subjects: 1868
Study 23931153 — intervention group
Group type: COMPARATOR
Intervention: Women of Black, Asian, Pacific Islander, or other race/ethnicity
Number of subjects: 1868
Study 23931153 — intervention group
Group type: COMPARATOR
Intervention: Women reporting substance use problems
Number of subjects: 1868
Study 23931153 — intervention group
Group type: COMPARATOR
Intervention: Women reporting IPV
Number of subjects: 1868
Study 22829506 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium-nitride-oxide-coated bioactive stents (BAS)
Number of subjects: 827
Study 22829506 — intervention group
Group type: COMPARATOR
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 827
Study 20586001 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant A
Number of subjects: 0
Study 20586001 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant B
Number of subjects: 0
Study 17079060 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (The Chronic Disease Self-Management Course, Lorig et al., 2001)
Number of subjects: 100
Study 17079060 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 17079060 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 100
Study 15738503 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg)
Number of subjects: 358
Study 15738503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study 12197845 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 37
Study 12197845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 9787686 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV‐IGIV, 750 mg/kg, monthly
Number of subjects: 416
Study 9787686 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infusions)
Number of subjects: 416
Study 7664857 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 1 mg daily
Number of subjects: 671
Study 7664857 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate, 2 mg daily
Number of subjects: 671
Study 7664857 — intervention group
Group type: COMPARATOR
Intervention: Budesonide, 1.6 mg daily
Number of subjects: 671
Study 2523772 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide (100 mg x 2/day)
Number of subjects: 40
Study 2523772 — intervention group
Group type: COMPARATOR
Intervention: phenylprenazone (200 mg x 2/day)
Number of subjects: 40
Study 730841 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach services
Number of subjects: 7000
Study 730841 — intervention group
Group type: COMPARATOR
Intervention: No outreach services (Control)
Number of subjects: 7000
Study 31285038 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural intervention delivered by mental health nurse practitioners (MHNPs), consisting of six sessions.
Number of subjects: 198
Study 31285038 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 198
Study 28585163 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based quality improvement (EBQI)
Number of subjects: 87
Study 28585163 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder engagement through regional data presentation
Number of subjects: 87
Study 28585163 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews with stakeholders
Number of subjects: 87
Study 28585163 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-professional, multilevel stakeholder engagement
Number of subjects: 87
Study 26032197 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction (via a computer game or TV watching)
Number of subjects: 0
Study 26032197 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention to eating
Number of subjects: 0
Study 26032197 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 0
Study 26032197 — intervention group
Group type: EXPERIMENTAL
Intervention: Focusing on eating
Number of subjects: 0
Study 23574691 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week hatha yoga program, three sessions per week (50 min per session)
Number of subjects: 37
Study 23574691 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 37
Study 21277410 — intervention group
Group type: EXPERIMENTAL
Intervention: trivalent recombinant hemagglutinin (rHA) vaccine, 45 μg HA/strain
Number of subjects: 601
Study 21277410 — intervention group
Group type: COMPARATOR
Intervention: U.S. licensed trivalent inactivated vaccine (TIV), 15 μg HA/strain
Number of subjects: 601
Study 21277410 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 601
Study 21277410 — intervention group
Group type: EXPERIMENTAL
Intervention: trivalent recombinant hemagglutinin (rHA) vaccine
Number of subjects: 601
Study 18077012 — intervention group
Group type: COMPARATOR
Intervention: 0.5 g Vit-C/day
Number of subjects: 36
Study 18077012 — intervention group
Group type: COMPARATOR
Intervention: 1 g Vit-C/day
Number of subjects: 36
Study 18077012 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 36
Study 16452740 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (1 mL of 10 mg/mL)
Number of subjects: 20
Study 16452740 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (1 mL of phosphate-buffered saline)
Number of subjects: 20
Study 15043521 — intervention group
Group type: EXPERIMENTAL
Intervention: Motilin (4 pmol.min/kg)
Number of subjects: 53
Study 15043521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 11043126 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte transplantation (ACT)
Number of subjects: 20
Study 11043126 — intervention group
Group type: COMPARATOR
Intervention: Osteochondral cylinder transplantation (OCT)
Number of subjects: 20
Study 9280177 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble fiber diet
Number of subjects: 33
Study 8320622 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein diet for 8 weeks
Number of subjects: 23
Study 8320622 — intervention group
Group type: COMPARATOR
Intervention: Standard low fat, low cholesterol diet
Number of subjects: 23
Study 8320622 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard low fat, low cholesterol diet after 8 weeks of soy protein diet
Number of subjects: 23
Study 8320622 — intervention group
Group type: COMPARATOR
Intervention: Soy protein diet after 8 weeks of standard low fat, low cholesterol diet
Number of subjects: 23
Study 3548603 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent alarm device
Number of subjects: 44
Study 3548603 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contingent alarm device
Number of subjects: 44
Study 3548603 — intervention group
Group type: COMPARATOR
Intervention: Both alarm devices
Number of subjects: 44
Study 31512487 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of beans, grains, milk, fruits, and vegetables
Number of subjects: 3397
Study 31512487 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher consumption of eggs and potatoes
Number of subjects: 3397
Study 31512487 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of vitamin D, chloride, total serum protein, and red blood cell folate
Number of subjects: 3397
Study 31512487 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of C‐reactive protein and vitamin B12
Number of subjects: 3397
Study 30348219 — intervention group
Group type: EXPERIMENTAL
Intervention: Health facility delivery
Number of subjects: 309
Study 30348219 — intervention group
Group type: COMPARATOR
Intervention: Home delivery
Number of subjects: 309
Study 30348219 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint decision-making with husbands
Number of subjects: 309
Study 30348219 — intervention group
Group type: EXPERIMENTAL
Intervention: Husbands choose health facility delivery
Number of subjects: 309
Study 30348219 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium wealth status
Number of subjects: 309
Study 30348219 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to health facility within 2 km
Number of subjects: 309
Study 30348219 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional means of transport
Number of subjects: 309
Study 30348219 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading newspapers daily or infrequently
Number of subjects: 309
Study 30348219 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge about complications during delivery
Number of subjects: 309
Study 30348219 — intervention group
Group type: EXPERIMENTAL
Intervention: Good perception on quality of care received
Number of subjects: 309
Study 30348219 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous facility delivery
Number of subjects: 309
Study 30348219 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative experiences of delivery outcomes in community
Number of subjects: 309
Study 30348219 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of home delivery as life threatening
Number of subjects: 309
Study 27665206 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist treatment (e.g., warfarin)
Number of subjects: 2718
Study 27665206 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 2718
Study 27665206 — intervention group
Group type: COMPARATOR
Intervention: Black race
Number of subjects: 2718
Study 27665206 — intervention group
Group type: COMPARATOR
Intervention: New York Heart Association class IV
Number of subjects: 2718
Study 27665206 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin >13.5 g/dl
Number of subjects: 2718
Study 27665206 — intervention group
Group type: EXPERIMENTAL
Intervention: New York Heart Association class I
Number of subjects: 2718
Study 27665206 — intervention group
Group type: COMPARATOR
Intervention: US sites
Number of subjects: 2718
Study 27665206 — intervention group
Group type: COMPARATOR
Intervention: SAMe‐TT2R2 scores of 4 or higher
Number of subjects: 2718
Study 27665206 — intervention group
Group type: COMPARATOR
Intervention: SAMe‐TT2R2 scores of 1
Number of subjects: 2718
Study 27665206 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SAMe‐TT2R2 score
Number of subjects: 2718
Study 24642648 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal lactoferrin (LF) 300 mg administered 4 hours before amniocentesis
Number of subjects: 60
Study 24642648 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal lactoferrin (LF) 300 mg administered 12 hours before amniocentesis
Number of subjects: 60
Study 24642648 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 60
Study 22372573 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored multi-faceted improvement programme
Number of subjects: 119
Study 22372573 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 119
Study 19616895 — intervention group
Group type: EXPERIMENTAL
Intervention: 10mg of hydrocortisone
Number of subjects: 32
Study 19616895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 19616895 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 32
Study 18622175 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.6 g/kg)
Number of subjects: 0
Study 18622175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16267768 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose sulfadoxine-pyrimethamine (S-P)
Number of subjects: 63
Study 16267768 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 11867042 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg/day
Number of subjects: 18
Study 11867042 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 10190768 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased carbohydrate condition (39.4% CHO)
Number of subjects: 15
Study 10190768 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased carbohydrate condition (59.2% CHO)
Number of subjects: 15
Study 10190768 — intervention group
Group type: COMPARATOR
Intervention: Normal mixed diet (53.6% CHO)
Number of subjects: 15
Study 10190768 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (52.7% CHO)
Number of subjects: 15
Study 7756640 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin (ATG) and cyclosporine (CsA) administered simultaneously for 4 days and 6 months respectively
Number of subjects: 55
Study 2147837 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine (5 to 10 micrograms/Kg/mn)
Number of subjects: 40
Study 2147837 — intervention group
Group type: COMPARATOR
Intervention: Enoximone (1 mg/kg bolus followed by intravenous infusion of 5 to 10 micrograms/Kg/mn)
Number of subjects: 40
Study 6768081 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 6768081 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 0
Study 31612653 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox
Number of subjects: 24
Study 31612653 — intervention group
Group type: COMPARATOR
Intervention: Neuronox
Number of subjects: 24
Study 31612653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Botox and Neuronox
Number of subjects: 24
Study 29037641 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 31
Study 29037641 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (SG)
Number of subjects: 31
Study 26527536 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous extract of noble kava cultivar (standardised to 240 mg of kavalactones per day)
Number of subjects: 210
Study 26527536 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 210
Study 23098762 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 100 U
Number of subjects: 563
Study 23098762 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 200 U
Number of subjects: 563
Study 23098762 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 300 U
Number of subjects: 563
Study 23098762 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 563
Study 23098762 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (all doses)
Number of subjects: 563
Study 22045820 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mailing of faecal occult blood tests (FOBT)
Number of subjects: 7415
Study 22045820 — intervention group
Group type: COMPARATOR
Intervention: Standard invitation
Number of subjects: 7415
Study 19370699 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate smoking trajectory (74.6% of participants)
Number of subjects: 268
Study 19370699 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smoking trajectory (remaining participants)
Number of subjects: 268
Study 16150010 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion‐cognition focused program
Number of subjects: 96
Study 12575787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant (2-5 cm3)
Number of subjects: 55
Study 12575787 — intervention group
Group type: COMPARATOR
Intervention: Control (no fibrin sealant)
Number of subjects: 55
Study 10571630 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine hydrochloride gel at 4 degrees C
Number of subjects: 60
Study 10571630 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine hydrochloride gel at 40 degrees C
Number of subjects: 60
Study 10571630 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine hydrochloride gel at 22 degrees C (control group)
Number of subjects: 60
Study 8729491 — intervention group
Group type: EXPERIMENTAL
Intervention: Client centred hypnotherapy (CCH)
Number of subjects: 86
Study 8729491 — intervention group
Group type: COMPARATOR
Intervention: Counselling
Number of subjects: 86
Study 1899079 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin 1200 micrograms/day intranasally (n = 22)
Number of subjects: 42
Study 1899079 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery (n = 20)
Number of subjects: 42
Study 6352001 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial therapy directed at the poor-prognosis component of tumors
Number of subjects: 323
Study 6352001 — intervention group
Group type: EXPERIMENTAL
Intervention: Further biopsy at the time of relapse
Number of subjects: 323
Study 31805968 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation toolkit (arm 1)
Number of subjects: 29
Study 31805968 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit + in-person training + training webinars (arm 2)
Number of subjects: 29
Study 31805968 — intervention group
Group type: EXPERIMENTAL
Intervention: Toolkit + training + webinars + offered practice facilitation (arm 3)
Number of subjects: 29
Study 31805968 — intervention group
Group type: COMPARATOR
Intervention: Non-study CHCs
Number of subjects: 29
Study 28767271 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS plus exercise therapy (TG)
Number of subjects: 23
Study 28767271 — intervention group
Group type: COMPARATOR
Intervention: Sham TEAS plus exercise therapy (CG)
Number of subjects: 23
Study 26814294 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-639 (100 mg)
Number of subjects: 19
Study 26814294 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (300 mg)
Number of subjects: 19
Study 26814294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 24952366 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective care pathway
Number of subjects: 105
Study 24952366 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 30‐39.9 kg/m²
Number of subjects: 105
Study 24952366 — intervention group
Group type: COMPARATOR
Intervention: BMI >40 kg/m²
Number of subjects: 105
Study 22377591 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling for prevention of weight gain
Number of subjects: 40
Study 22377591 — intervention group
Group type: COMPARATOR
Intervention: Dietary intakes of n3 fatty acids, BMI, serum levels of carotenoids, TV hours watched/day
Number of subjects: 40
Study 19583074 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 60
Study 19583074 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo cream
Number of subjects: 60
Study 17421001 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-saliva collection device (Oragene DNA collection kit)
Number of subjects: 17
Study 17421001 — intervention group
Group type: COMPARATOR
Intervention: Oral rinse
Number of subjects: 17
Study 17421001 — intervention group
Group type: COMPARATOR
Intervention: Foam swab
Number of subjects: 17
Study 17421001 — intervention group
Group type: COMPARATOR
Intervention: Cytobrush
Number of subjects: 17
Study 17421001 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-saliva and oral-rinse samples
Number of subjects: 17
Study 15791633 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT) for 12 weeks
Number of subjects: 24
Study 15791633 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 24
Study 12784700 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9862579 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosome 5 allelic losses (LOH) in ampullary tumours
Number of subjects: 27